J&J Snaps Six Straight Sessions of Losses
Is Johnson & Johnson (JNJ) the Best Stock To Buy Right Now According To Billionaire Cliff Asness?
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
J&J to Shutter Cardiovascular, Metabolic Drug Unit: Report
Johnson & Johnson (JNJ): Leveraging Innovation for Sustained Market Leadership
Johnson & Johnson (JNJ): A Good Holding Company Stock to Buy Now
Amgen, Visa Share Losses Lead Dow's 100-Point Drop
Johnson & Johnson (JNJ): Hedge Funds Are Bullish On This Trending AI Stock Right Now
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Bristol Myers, 2seventy Bio Halt Enrollment in Abecma Late-stage Trial
Johnson & Johnson (JNJ.US) EGFR/cMET dual monoclonal antibody "Evantuzumab subcutaneous injection formulation" applied for market approval.
Johnson & Johnson (JNJ.US) has filed for market approval for the EGFR/cMET dual anti-Everolimus monoclonal antibody subcutaneous injection formulation.
J&J Unit Third Bankruptcy Attempt Location to Be Determined by Texas Judge
Analysts Agree That Kenvue's Neutrogena Needs a Face-lift
J&J's Bankruptcy Effort Fails High Court Test, Holdouts Say
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
10 Health Care Stocks With Whale Alerts In Today's Session
J&J Needs to End Talc Lawsuits. The Third Time Could Be the Charm. -- Barrons.com
Express News | Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Johnson & Johnson Marks 50 Years In Singapore With Range Of Events